<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04840511</url>
  </required_header>
  <id_info>
    <org_study_id>NETosis-prostate Ca</org_study_id>
    <nct_id>NCT04840511</nct_id>
  </id_info>
  <brief_title>The Effect of Perioperative Lidocaine Infusion on Neutrophil Extracellular Trapping</brief_title>
  <official_title>The Effect of Perioperative Lidocaine Infusion on Neutrophil Extracellular Trapping in the Patients Undergoing the Robot-assisted Prostatectomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Catholic University of Korea</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Catholic University of Korea</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will be done to investigate perioperative lidocaine infusion on neutrophil&#xD;
      extracellular trapping in the patients undergoing the robot-assisted prostatectomy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Neutrophil extracellular trapping by analyzing the meyloperoxidase, neutrophil elastase,&#xD;
      citrullinated histone3&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 27, 2021</start_date>
  <completion_date type="Anticipated">September 27, 2022</completion_date>
  <primary_completion_date type="Anticipated">September 27, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Concentration of citrullinated histone3</measure>
    <time_frame>24 hours after surgery</time_frame>
    <description>This will be obtained using ELISA.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Concentration of meyloperoxidase</measure>
    <time_frame>24 hours after surgery</time_frame>
    <description>This will be obtained using ELISA.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration of neutrophil elastase</measure>
    <time_frame>24 hours after surgery</time_frame>
    <description>This will be obtained using ELISA.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>the severity of postoperative pain using NRS</measure>
    <time_frame>during postoperative 24 hours</time_frame>
    <description>This will be measured using NRS (numeric rating scale; 0=no pain, 10=the worst pain)</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Urologic Cancer</condition>
  <arm_group>
    <arm_group_label>lidocaine group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The study group receives perioperative lidocaine infusion with general anesthesia for robot-assisted prostatectomy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The control group receives normal saline infusion with with general anesthesia for robot-assisted prostatectomy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>lidocaine group</intervention_name>
    <description>lidocaine 1.5 mg/kg bolus (infused over 10 min) followed by 2.0 mg/kg/h during operation and 1.0 mg/kg/h during postoperative 24 hours (no more than 120 mg/h)</description>
    <arm_group_label>lidocaine group</arm_group_label>
    <other_name>lidocaine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>control group</intervention_name>
    <description>normal saline 0.15 ml bolus followed by 0.15 ml/kg/hr during operation and 0.2 ml/kg/hr during postoperative 24 hours</description>
    <arm_group_label>control group</arm_group_label>
    <other_name>normal saline</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  patients scheduled robot-assisted prostatectomy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  lidocaine allergy Hx&#xD;
&#xD;
          -  hemodynamic unstable patients&#xD;
&#xD;
          -  weight &lt; 40kg&#xD;
&#xD;
          -  arrhythmia or bradycardia&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Young Eun Moon, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul St. Mary's Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Young Eun Moon, MD, PhD</last_name>
    <phone>822-2258-6163</phone>
    <email>0910momo@naver.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Seoul St.Mary's Hospital</name>
      <address>
        <city>Seoul</city>
        <state>Seocho-gu</state>
        <zip>07651</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Young Eun Moon, Md, PhD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>April 7, 2021</study_first_submitted>
  <study_first_submitted_qc>April 7, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 12, 2021</study_first_posted>
  <last_update_submitted>September 26, 2021</last_update_submitted>
  <last_update_submitted_qc>September 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The Catholic University of Korea</investigator_affiliation>
    <investigator_full_name>Young Eun Moon</investigator_full_name>
    <investigator_title>Associate professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urologic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lidocaine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

